Mark Purcell
Stock Analyst at Morgan Stanley
(1.04)
# 3,658
Out of 4,876 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $120.01 | -5.01% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $47.85 | +14.94% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $38.58 | +14.05% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $69.85 | +21.69% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $68.51 | +75.16% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $120.01
Upside: -5.01%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $47.85
Upside: +14.94%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $38.58
Upside: +14.05%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $69.85
Upside: +21.69%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $68.51
Upside: +75.16%